Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Harrow Health (NASDAQ:HROW) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 15,825 shares of the company’s stock, valued at approximately $138,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.06% of Harrow Health at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in HROW. Acadian Asset Management LLC acquired a new position in Harrow Health in the first quarter valued at approximately $1,983,000. Westside Investment Management Inc. acquired a new position in Harrow Health in the second quarter valued at approximately $199,000. Stone Ridge Asset Management LLC lifted its stake in Harrow Health by 35.2% in the second quarter. Stone Ridge Asset Management LLC now owns 14,874 shares of the company’s stock valued at $129,000 after buying an additional 3,874 shares during the period. H D Vest Advisory Services acquired a new position in shares of Harrow Health during the second quarter worth approximately $123,000. Finally, Wedge Capital Management L L P NC acquired a new position in shares of Harrow Health during the second quarter worth approximately $1,330,000. Institutional investors own 34.41% of the company’s stock.
HROW has been the topic of a number of research reports. Zacks Investment Research raised Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 target price on the stock in a research report on Friday, September 6th. ValuEngine raised Harrow Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Finally, Lake Street Capital set a $15.00 target price on Harrow Health and gave the stock a “buy” rating in a research report on Friday, August 16th.
NASDAQ HROW traded down $0.37 on Friday, reaching $5.83. The company had a trading volume of 8,680 shares, compared to its average volume of 315,672. The stock has a market capitalization of $154.27 million, a P/E ratio of 9.66 and a beta of 0.15. The company has a quick ratio of 3.60, a current ratio of 3.87 and a debt-to-equity ratio of 0.56. The company’s fifty day moving average is $6.22 and its 200 day moving average is $6.06. Harrow Health has a 52-week low of $2.22 and a 52-week high of $8.99.
Harrow Health (NASDAQ:HROW) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $13.52 million during the quarter, compared to the consensus estimate of $12.55 million. Harrow Health had a net margin of 51.32% and a return on equity of 50.32%. On average, research analysts expect that Harrow Health will post -0.06 EPS for the current year.
In related news, Director Robert J. Kammer sold 6,500 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $6.89, for a total transaction of $44,785.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold a total of 19,500 shares of company stock worth $133,055 in the last three months. 12.43% of the stock is currently owned by insiders.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Read More: Average Daily Trade Volume – ADTV
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.